Literature DB >> 22351718

Hepatitis C: the end of the beginning and possibly the beginning of the end.

Harvey J Alter, T Jake Liang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22351718      PMCID： PMC3480337          DOI： 10.7326/0003-4819-156-4-201202210-00014

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  14 in total

1.  Evaluation of the effectiveness of targeted lookback for HCV infection in the United States-interim results.

Authors:  D H Culver; M J Alter; R J Mullan; H S Margolis
Journal:  Transfusion       Date:  2000-10       Impact factor: 3.157

2.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

3.  The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

Authors:  Stefan Zeuzem; Peter Buggisch; Kosh Agarwal; Patrick Marcellin; Daniel Sereni; Hartwig Klinker; Christophe Moreno; Jean-Pierre Zarski; Yves Horsmans; Hongmei Mo; Sarah Arterburn; Steven Knox; David Oldach; John G McHutchison; Michael P Manns; Graham R Foster
Journal:  Hepatology       Date:  2012-03       Impact factor: 17.425

Review 4.  Peginterferon and ribavirin for chronic hepatitis C.

Authors:  Jay H Hoofnagle; Leonard B Seeff
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

5.  Boceprevir for untreated chronic HCV genotype 1 infection.

Authors:  Fred Poordad; Jonathan McCone; Bruce R Bacon; Savino Bruno; Michael P Manns; Mark S Sulkowski; Ira M Jacobson; K Rajender Reddy; Zachary D Goodman; Navdeep Boparai; Mark J DiNubile; Vilma Sniukiene; Clifford A Brass; Janice K Albrecht; Jean-Pierre Bronowicki
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

6.  Institute of Medicine recommendations for the prevention and control of hepatitis B and C.

Authors:  Abigail E Mitchell; Heather M Colvin; R Palmer Beasley
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

7.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

8.  Telaprevir for retreatment of HCV infection.

Authors:  Stefan Zeuzem; Pietro Andreone; Stanislas Pol; Eric Lawitz; Moises Diago; Stuart Roberts; Roberto Focaccia; Zobair Younossi; Graham R Foster; Andrzej Horban; Peter Ferenci; Frederik Nevens; Beat Müllhaupt; Paul Pockros; Ruben Terg; Daniel Shouval; Bart van Hoek; Ola Weiland; Rolf Van Heeswijk; Sandra De Meyer; Don Luo; Griet Boogaerts; Ramon Polo; Gaston Picchio; Maria Beumont
Journal:  N Engl J Med       Date:  2011-06-23       Impact factor: 91.245

Review 9.  The hepatitis C virus life cycle as a target for new antiviral therapies.

Authors:  Jean-Michel Pawlotsky; Stéphane Chevaliez; John G McHutchison
Journal:  Gastroenterology       Date:  2007-05       Impact factor: 22.682

10.  Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

Authors:  Gary L Davis; Miriam J Alter; Hashem El-Serag; Thierry Poynard; Linda W Jennings
Journal:  Gastroenterology       Date:  2009-10-25       Impact factor: 22.682
View more
  19 in total

1.  Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study.

Authors:  Jenny Iversen; Handan Wand; Libby Topp; John Kaldor; Lisa Maher
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

2.  Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.

Authors:  Sunil Suhas Solomon; Shruti H Mehta; Aylur K Srikrishnan; Suniti Solomon; Allison M McFall; Oliver Laeyendecker; David D Celentano; Syed H Iqbal; Santhanam Anand; Canjeevaram K Vasudevan; Shanmugam Saravanan; Gregory M Lucas; Muniratnam S Kumar; Mark S Sulkowski; Thomas C Quinn
Journal:  Lancet Infect Dis       Date:  2014-12-03       Impact factor: 25.071

3.  Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991-2012.

Authors:  Bohdan Nosyk; Libo Li; Elizabeth Evans; Darren Urada; David Huang; Evan Wood; Richard Rawson; Yih-Ing Hser
Journal:  Drug Alcohol Depend       Date:  2014-07-27       Impact factor: 4.492

4.  Arabinoxylan rice bran (Biobran) suppresses the viremia level in patients with chronic HCV infection: A randomized trial.

Authors:  Hosny Salama; Eman Medhat; Magda Shaheen; Abdel-Rahman N Zekri; Tarneem Darwish; Mamdooh Ghoneum
Journal:  Int J Immunopathol Pharmacol       Date:  2016-10-31       Impact factor: 3.219

5.  Hepatitis C screening: getting it right.

Authors:  Brian R Edlin
Journal:  Hepatology       Date:  2012-12-24       Impact factor: 17.425

6.  Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein.

Authors:  Hongying Duan; Alla Kachko; Lilin Zhong; Evi Struble; Shivani Pandey; Hailing Yan; Christine Harman; Maria Luisa Virata-Theimer; Lu Deng; Zhong Zhao; Marian Major; Stephen Feinstone; Pei Zhang
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

7.  A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus.

Authors:  Christine Harman; Lilin Zhong; Li Ma; Peter Liu; Lu Deng; Zhong Zhao; Hailing Yan; Evi Struble; Maria Luisa Virata-Theimer; Pei Zhang
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

8.  Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness.

Authors:  Timothy Sheahan; Naoko Imanaka; Svetlana Marukian; Marcus Dorner; Peng Liu; Alexander Ploss; Charles M Rice
Journal:  Cell Host Microbe       Date:  2014-02-12       Impact factor: 21.023

Review 9.  Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.

Authors:  E Cariani; L Roli; G Missale; E Villa; C Ferrari; T Trenti
Journal:  Pharmacogenomics J       Date:  2015-04-28       Impact factor: 3.550

Review 10.  Best strategies for global HCV eradication.

Authors:  Liesl M Hagan; Raymond F Schinazi
Journal:  Liver Int       Date:  2013-02       Impact factor: 5.828
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.